<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719574</url>
  </required_header>
  <id_info>
    <org_study_id>2102-HEM-101</org_study_id>
    <nct_id>NCT02719574</nct_id>
  </id_info>
  <brief_title>Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation</brief_title>
  <official_title>A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forma Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forma Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib)
      as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the
      study is split into 2 distinct parts: a dose escalation part, which will utilize an
      open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) +
      azacitidine (combination agent) administered via one or more intermittent dosing schedules
      followed by a dose expansion part. The dose expansion part will enroll patients in up to 5
      expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as
      combination activity with azacitidine or cytarabine. Following the completion of the relevant
      Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different
      cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102
      (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Doses (MTDs) or Maximum Evaluated Doses (MEDs) [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a Dose Limiting Toxicity (DLT) [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Doses recommended for future studies [Phase 1]</measure>
    <time_frame>Within first 4 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR and CRh) Rate of FT-2102 (olutasidenib) single-agent or in combination with Azacitidine in patients with AML/MDS [Phase 2 Cohorts 1, 3-8]</measure>
    <time_frame>As per modified IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>4-Month Relapse Free Survival (RFS) of FT-2102 (olutasidenib) single-agent [Phase 2 Cohort 2]</measure>
    <time_frame>From time of entry on study through progression, up to 30 weeks, on average</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of peak plasma concentration Tmax [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for half of the drug to be absent in blood stream following dose (T 1/2) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate at which drug is removed from blood stream (CL/F) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of drug distribution within the blood stream (Vd/F) [Phase 1 and Phase 2]</measure>
    <time_frame>Blood samples for PK analysis collected at multiple visits during the first 60 days of treatment and on day 1 of all cycles following the first 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of antileukemic or antimyelodysplastic activity of FT-2102 (olutasidenib) as determined by CR, CRh, CRi, MLFS, Marrow CR, PR, and SD as a single-agent or in combination with azacitidine or cytarabine [Phase 1]</measure>
    <time_frame>As per modified IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, clinical laboratory abnormalities, and changes in ECG parameters as assessed by CTCAE v4.0 as a single-agent or in combination with azacitidine [Phase 2]</measure>
    <time_frame>Safety will be assessed from time of first dose through 28 days post last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional measures of antileukemic or antimyelodysplastic activity as determined by CRi, MLFS, Marrow CR, PR, Overall Response (OR), and Stable Disease (SD) of FT-2102 (olutasidenib) alone or in combination with azacitidine [Phase 2]</measure>
    <time_frame>As per modified IWG Response Assessment Guidelines for AML and MDS based on investigator's assessment on day 1 of each cycle through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) [Phase 2]</measure>
    <time_frame>From first dose of study drug through time of first response by blood recovery count, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) [Phase 2]</measure>
    <time_frame>From time of first response by blood recovery count through relapse, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) [Phase 2]</measure>
    <time_frame>From time of entry on study through progression, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) [Phase 2]</measure>
    <time_frame>From time of entry on study through death or date last known alive at end of follow-up, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (RFS) [Phase 2]</measure>
    <time_frame>From time of entry on study through progression, up to 30 weeks, on average</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>PH1 Dose Escalation &amp; Expansion FT-2102 (olutasidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed or Refractory (R/R) AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R/R AML/MDS, previously treated with an IDH1 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R/R AML/MDS that have been previously treated with single-agent IDH1 inhibitor therapy as their last therapy prior to study enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment naïve AML for whom standard treatments are contraindicated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment naïve AML who are candidates for azacitidine first line treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT-2102 (olutasidenib)</intervention_name>
    <description>FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level</description>
    <arm_group_label>PH1 Dose Escalation &amp; Expansion FT-2102 (olutasidenib)</arm_group_label>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine</arm_group_label>
    <arm_group_label>PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent</arm_group_label>
    <arm_group_label>PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>azacitidine will be administered per site's standard of care</description>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <arm_group_label>PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>low-dose cytarabine will be administered per site's standard of care</description>
    <arm_group_label>PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven acute myeloid leukemia (AML) (except acute promyelocytic
             leukemia [APL] with the t(15;17) translocation) or intermediate, high-risk, or very
             high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization
             (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is
             relapsed or refractory (R/R) to standard therapy and/or for which standard therapy is
             contraindicated or which has not adequately responded to standard therapy.

          -  Patients must have documented IDH1-R132 gene-mutated disease as evaluated by the site

          -  Good performance status

          -  Good kidney and liver function

        Exclusion Criteria:

          -  Patients with symptomatic central nervous system (CNS) metastases or other tumor
             location (such as spinal cord compression, other compressive mass, uncontrolled
             painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention,
             palliative care, surgery or radiation therapy

          -  Congestive heart failure (New York Heart Association Class III or IV) or unstable
             angina pectoris. Previous history of myocardial infarction within 1 year prior to
             study entry, uncontrolled hypertension or uncontrolled arrhythmias

          -  Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe
             symptoms) with current medication

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <phone>310-794-0242</phone>
      <email>bhabtemariam@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linh Dang-Chu</last_name>
      <phone>916-734-5930</phone>
      <email>ldangchu@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Malak</last_name>
      <phone>203-785-4699</phone>
      <email>Tanya.Malak@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Englund</last_name>
      <phone>305-243-6899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirra Dinner, MD</last_name>
      <phone>312-472-1234</phone>
      <email>Shira.Dinner@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Research, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <email>melanie.Coleman@franciscanalliance.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxia Li</last_name>
      <phone>410-328-8370</phone>
      <email>hongxiali@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Garn</last_name>
      <phone>313-576-9685</phone>
      <email>garnt@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office</last_name>
      <phone>800-767-9355</phone>
      <email>askroswell@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Cancer Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Baskind</last_name>
      <email>Paul_Baskind@nymc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Leach</last_name>
      <phone>212-304-5585</phone>
      <email>sl3971@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornell University Weill Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Lascu</last_name>
      <phone>212-746-0974</phone>
      <email>ell2028@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heme/Onc. Clinical Trials Office</last_name>
      <phone>919-681-4769</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Brenner</last_name>
      <email>Lisa.Brenner@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chase Brockett</last_name>
      <phone>503-346-0227</phone>
      <email>brocketc@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Walls</last_name>
      <email>sarah.walls@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Taylor</last_name>
      <phone>615-936-1936</phone>
      <email>Rebekah.J.Taylor@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prapti Patel, MD</last_name>
      <phone>214-648-3111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Towne</last_name>
      <phone>346-238-2006</phone>
      <email>atowne@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, MD</last_name>
      <phone>713-794-5783</phone>
      <email>jcortes@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital &amp; Health Service</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nada Hamad, MD</last_name>
      <phone>+61 02 8382 1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Devendra Hiwase, MD</last_name>
      <phone>+61 (08) 7074 0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wei, MD</last_name>
      <email>andrew.wei@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Cancer Care Center</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Bajel, MD</last_name>
      <phone>+61 (03) 8559 5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Grove, MD</last_name>
      <phone>+61 (08) 6457 3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital, Monash University and Eastern Health Clinical School</name>
      <address>
        <city>Box Hill</city>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Schwarer, MD</last_name>
      <phone>+ 61 3 8804 9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Sanfelice</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2867</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, Hôpital Avicenne-APHP-Université Paris</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douay Angelique</last_name>
      <phone>+33(0)-1 48 95 75 05</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille (AP-HM) - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regis Costello</last_name>
      <email>recherche.costello@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peterlin</last_name>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, MD</last_name>
      <phone>+33(0)-1 42 49 49 49</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Est Parisien Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ollivier Legrand, MD</last_name>
      <phone>+33(0)-1 49 28 20 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) Bordeaux - Hospitaux du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Sauvezie</last_name>
      <phone>+33(0)-5 57 62 31 09</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Thomas, MD</last_name>
      <phone>+33(0)- 8 25 08 25 69</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislas Nimubona, MD</last_name>
      <phone>+33(0)- 2 99 28 43 21</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Recher, MD</last_name>
      <phone>+33(0)- 5 31 15 63 32</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nancy - Hopital Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Bonmati</last_name>
      <email>c.bonmati@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houssaini Soufyan</last_name>
      <phone>+33(0)-1 42 11 48 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Rieger</last_name>
      <email>kathrin.rieger@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Streitbürger</last_name>
      <phone>+495315953700</phone>
      <email>o.streitbuerger@klinikum-braunschweig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH - Klinik fuer Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Schaarschmidt</last_name>
      <phone>+49 371 333 43072</phone>
      <email>k.schaarschmidt@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH - Klinik fuer Innere Medizin</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Neubauer</last_name>
      <email>sekretariat.onkologie@med.uni-marburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeszentrum fuer Zell- und Gentherapie</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifa Al-Ali</last_name>
      <email>haifa.al-ali@uk-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ernst</last_name>
      <email>Thomas.Ernst@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Medizinische Klinik A, Hämatologie, Hämostaseologi</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Böwing</last_name>
      <phone>+49 251 8344386</phone>
      <email>christin.boewing@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus (RBK) Onkologisches Zentrum</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann</last_name>
      <email>martin.kaufmann@rbk.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU S. Luigi Gonzaga - Orbassano</name>
      <address>
        <city>Orbassano</city>
        <state>Turin</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Marini, MD</last_name>
      <phone>+39 11 9026709</phone>
      <email>silvia.marini01@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Mazzoni - UOC Ematologia Ascoli Piceno</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Galieni</last_name>
      <email>piero.galieni@sanita.marche.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Curti</last_name>
      <email>antonio.curti2@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica - IRST IRCC</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Martinelli</last_name>
      <email>giovanni.martinelli@irst.emr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Roti</last_name>
      <email>giovanni.roti@unipr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Lanza</last_name>
      <email>Francesco.lanza@auslromagna.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Rimini Hematology, Department of Oncology and Hematoloy</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Mianulli</last_name>
      <email>annamaria.mianulli@auslromagna.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umberto I Pol. di Roma-Università di Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eros Dibona</last_name>
      <email>eros.dibona@aulss8.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Kyun Sohn, MD</last_name>
      <phone>(82)-2-2228-5800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gumi</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Me Bang, MD</last_name>
      <phone>+82 1588-3369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Soo Yoon, MD</last_name>
      <phone>+82-2-2072-0505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>June Won Cheong, MD</last_name>
      <phone>+82 53 200 2040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chul Won Jung, MD</last_name>
      <phone>+82-2-3410-0200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Salamero, MD</last_name>
      <phone>+34 934 89 48 94</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Esteve, MD</last_name>
      <phone>+ 34 93 227 54 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia-Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>8908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Arnan-Sangerman, MD</last_name>
      <phone>+34 932 60 77 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Figuera</last_name>
      <email>a.figueraalvarez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Martinez Lopez, MD</last_name>
      <phone>+34 913 90 80 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>START - Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Vidriales</last_name>
      <email>mbvidriales@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Colorado, MD</last_name>
      <phone>+34 942 20 25 20</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montesinos, MD</last_name>
      <phone>+34 961 24 40 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L78XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Patel</last_name>
      <email>amit.patel@liverpool.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Browndson</last_name>
      <phone>0203 456 7890</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. George's University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Klammer</last_name>
      <email>Matthias.Klammer@stgeorges.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Quek</last_name>
      <email>lynn.quek@ouh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Dalley</last_name>
      <email>Christopher.Dalley@uhs.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taussig, MD</last_name>
      <email>HaematoOncRN@rmh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>IDH1</keyword>
  <keyword>IDH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

